Phospho-specific antibodies’ typical purpose is to enable researchers to detect changes in proteins. They will exclusively bind to the amino acid sequence on a protein that has been phosphorylated (which is both a physical & chemical change) and do not bind to the same amino acid sequence on said protein if it lacks said phosphorylation. This aids in being able to clearly see and understand the data produced from this particular protein modification.
Affinity Purified (Prepared from rabbit serum by affinity purification via sequential chromatography on phospho- and dephosphopeptide affinity columns.)
Affinity Purified (Prepared from rabbit serum by affinity purification via sequential chromatography on phospho- and dephosphopeptide affinity columns.)
Affinity Purified (Prepared from rabbit serum by affinity purification via sequential chromatography on phospho- and dephosphopeptide affinity columns.)
Affinity Purified (Prepared from rabbit serum by affinity purification via sequential chromatography on phospho- and dephosphopeptide affinity columns.)
Affinity Purified (Prepared from rabbit serum by affinity purification via sequential chromatography on phospho- and dephospho-peptide affinity columns.)
ICC (Immunocytochemistry) (Immunocytochemical labeling of ATM phosphorylation in calyculin A-treated A431 cells. The cells were labeled with rabbit polyclonal anti-ATM (Ser-794) (AP3631) antibody in the absence (Left) or presence (Right) of blocking peptide (AX3635). The antibody was detected using appropriate secondary antibody conjugated to DyLight 594.)
WB (Western Blot) (Western blot of human A431 cells treated with Calyculin A (100nM) for 30 min. Blot lanes were untreated (lanes 1, 3, & 5) or treated with lambda phosphatase (lanes 2, 4, & 6) then probed with anti-ATM (Ser-794) (lanes 1 & 2), anti-ATM (C-Terminal) (lanes 3 & 4), or anti-ATM (Ser-1981) (lanes 5 & 6).)
ICC (Immunocytochemistry) (Immunocytochemical labeling of caveolin-1 phosphorylation in rabbit spleen fibroblasts. The cells were treated with pervanadate (1mM) for 30 min, then fixed with paraformaldehyde and labeled with rabbit polyclonal Caveolin-1 (N-terminal region) and mouse monoclonal Caveolin-1 (Tyr-14) antibodies. The antibodies were detected using appropriate secondary antibodies conjugated to Cy3.)
WB (Western Blot) (Western blot image of human A431 cells unstimulated (lanes 1, 3, & 5) or stimulated with pervanadate (1mM) for 30 min (lanes 2, 4, & 6). The blots were probed with rabbit polyclonal caveolin-1 (N-term.) (lanes 1 & 2), mouse monoclonal caveolin-1 (Tyr-14) (lanes 3 & 4) or mouse monoclonal caveolin-1 (lanes 5 & 6).)
ICC (Immunocytochemistry) (Immunocytochemical labeling of phosphorylated CRMP2 in mouse C2C12 cells. The cells were probed with CRMP2 (C-terminal region) and CRMP2 (Thr-555) rabbit polyclonal antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3. The antibodies were used in the absence (left) or presence (right) of their respective blocking peptide (CX2165 or CX2255).)
WB (Western Blot) (Western blot of rat PC12 cells untreated (lanes 1 & 3) or treated with calyculin A (lanes 2 & 4). The blot was probed with anti-CRMP2 (C-terminal Region) antibody (lanes 1 & 2) or anti-CRMP2 (Thr-555) antibody (lanes 3 & 4).)
ICC (Immunocytochemistry) (Immunocytochemical labeling of JNK in control (Top row) or calyculin A-treated A431 cells (Bottom row). The cells were labeled with mouse monoclonal JNK (C-terminal region) (Left) or mouse monoclonal JNK (Thr-183/Tyr-185) (Right). The antibodies were detected using goat anti-mouse DyLight 594.)
WB (Western Blot) (Western blot analysis of PC12 cells untreated (lanes 1 & 3) or treated with calyculin A (100nM) for 30 minutes (lanes 2 & 4). The blot was probed with anti-JNK1 (lanes 1 & 2) or anti-JNK1 (T183/Y185) (lanes 3 & 4).)
ICC (Immunocytochemistry) (Immunocytochemical labeling of nNOS phosphorylation in rat PC12 cells differentiated with NGF. The cells were probed with mouse monoclonal (mAb) nNOS (NM4011), and rabbit polyclonal (pAb) nNOS (C-terminal region), nNOS (Tyr-895)/eNOS (Tyr-657), and nNOS (Tyr-1326)/iNOS (Tyr-1055). The antibodies were detected using appropriate secondary antibody conjugated to DyLight 594.)
WB (Western Blot) (Western blot analysis of humanuMbilical vein endothelial cells stimulated with pervanadate (1mM) for 30 min. (lanes 1, 3, & 5) then the blot was treated with alkaline phosphatase (lanes 2, 4, & 6). The blots were probed with anti-eNOS monoclonal antibody (NM2211; lanes 1 & 2), anti-eNOS (Tyr-657) phospho-specific antibody (NP4031; lanes 3 & 4), or anti-eNOS polyclonal antibody (NP2281; lanes 5 & 6).)
WB (Western Blot) (Western Blot: The EGF stimulated HUVEC cell Iysates were resolved onto 10% SDS-PAGE, transferred onto NC membrane, and followed by an immunoblotting with Rabbit anti AXL(Phosphospecific) (Cat# AAA71347) antibody (Lane 1 &2 ) at 1 :500.)
DB (Dot Blot) (STAT2 phospho Tyr689 pAb tested by dot blot analysis. Dot blot analysis was used to confirm the specificity of STAT2 phospho Tyr689 pAb for STAT2 phospho Tyr689. Phosphorylated peptides corresponding to the immunogen and related peptides were spotted onto PVDF and probed with the antibody at 1:10,000. The amount of peptide (picomoles) spotted is indicated next to each row. Lane 1: Unmodified Ser727 STAT1 peptide. Lane 2: Phospho Ser727 STAT1 peptide. Lane 3: Unmodified Tyr689 STAT2 peptide. Lane 4: Phospho Tyr689 STAT2 peptide. Lane 5: Unmodified Ser727 STAT3 peptide. Lane 6: Phospho Ser727 STAT3 peptide. Lane 7: Unmodified Tyr705 STAT3 peptide. Lane 8: Phospho Tyr705 STAT3 peptide. Lane 9: Unmodified Ser726 STAT5A/Ser731 STAT5B peptide. Lane 10: Phospho Ser726 STAT5A/Ser731 STAT5B peptide. Lane 11: Unmodified Tyr694 STAT5A/Tyr699 STAT5B peptide. Lane 12: Phospho Tyr694 STAT5A/Tyr699 STAT5B peptide.)
WB (Western Blot) (STAT2 phospho Tyr689 pAb tested by Western blot. HeLa whole-cell extract (20 ug per lane) was probed with STAT2 phospho Tyr689 pAb (1:500). Lane 1: No treatment. Lane 2: Cells treated with IFNa (2500 units/ml for 30 minutes).)
DB (Dot Blot) (STAT1 phospho Ser727 pAb tested by Dot blot. Dot blot analysis was used to confirm the specificity of 39633 for STAT1 phospho Ser727. Phosphorylated peptides corresponding to the immunogen and related peptides were spotted onto PVDF and probed with 39633 at 1:500. The amount of peptide (picomoles) spotted is indicated next to each row. Lane 1: unmodified Ser727 STAT1 peptide. Lane 2: phospho Ser727 STAT1 peptide. Lane 3: unmodified Tyr689 STAT2 peptide. Lane 4: phospho Tyr689 STAT2 peptide. Lane 5: unmodified Ser727 STAT3 peptide. Lane 6: phospho Ser727 STAT3 peptide. Lane 7: unmodified Tyr705 STAT3 peptide. Lane 8: phospho Tyr705 STAT3 peptide. Lane 9: unmodified Ser726 STAT5A/Ser731 STAT5B peptide. Lane 10: phospho Ser726 STAT5A/Ser731 STAT5B peptide. Lane 11: unmodified Tyr694 STAT5A/Tyr699 STAT5B peptide. Lane 12: phospho Tyr694 STAT5A/Tyr699 STAT5B)
WB (Western Blot) (STAT1 phospho Ser727 pAb tested by Western blot. Lanes 1&4: Untreated HeLa whole-cell extract (20 ug). Lane 2&5: Whole-cell extract (20 ug) of HeLa cells treated with IFNa (2500U/ml for 30 min.). Lanes 3&6: Whole-cell extract (20 ug) of COS-7 cells treated with IFNg (1000U/ml for 15 min.). Lanes 1-3 were probed with at 1:500. Lanes 4-6 probed with (STAT1 alpha pAb) at 1:1000.)
DB (Dot Blot) (RNA pol II CTD phospho Ser5 pAb tested by dot blot analysis. Dot blot analysis was used to confirm the specificity of RNA pol II CTD phospho Ser5 antibody for phospho-Ser5 of the RNA Pol II C-terminal domain heptad repeat. Modified and unmodified peptides were spotted onto PVDF and probed with the antibody at a dilution of 0.2 ug/ml. Decreasing amounts of peptide were spotted in each row. Lane 1: Peptide phosphorylated at CTD repeat serine 2. Lane 2: Unmodified CTD repeat serine 2 peptide. Lane 3: Peptide phosphorylated at CTD repeat serine 5. Lane 4: Unmodified CTD repeat serine 5 peptide.)
WB (Western Blot) (RNA pol II CTD phospho Ser5 antibody tested by Western blot. Nuclear extract of HeLa cells (20 ug) probed with RNA pol II CTD phospho Ser5 antibody at a dilution of 0.5 ug/ml.)
ChIP (Chromatin Immunoprecipitation) (RNA pol II CTD phospho Ser5 antibody tested by ChIP analysis. Chromatin IP performed using the ChIP-IT Express Kit and HeLa Chromatin (1.5 x 106 cell equivalents per ChIP) using 10 ug of RNA pol II CTD phospho Ser5 antibody or the equivalent amount of rabbit IgG as a negative control. Real time, quantitative PCR (RT-qPCR) was performed on DNA purified from each of the ChIP reactions using a primer pair specific for the PABPC1 gene. Data are presented as Fold Enrichment of the ChIP antibody signal versus the negative control IgG (arbitrarily assigned a value of 1) using the ddCT method.)
ChIP (Chromatin Immunoprecipitation) (RNA pol II CTD phospho Ser5 antibody (pAb) tested by ChIP-Seq. ChIP was performed using the ChIP-IT High Sensitivity Kit with chromatin from 2.3 million HL-60 cells and 4 ul of antibody. ChIP DNA was sequenced on the Illumina HiSeq and 26 million sequence tags were mapped to identify RNA pol II phospho Ser5 binding. The image shows a 1.2 million base pair region on chromosome 15 with the expected enrichment at gene promoters.)
DB (Dot Blot) (CENP-A phospho Ser18 antibody (pAb) tested by dot blot analysis. Dot blot analysis was used to confirm the specificity of CENP-A phospho Ser18 antibody. Peptides corresponding to the immunogen and related proteins were spotted onto PVDF and probed with the antibody at 1:750. The amount of peptide (picomoles) spotted is indicated next to each row. Lane 1: CENP-A phospho Ser 16 and phospho Ser18. Lane 2: CENP-A unmodified. Lane 3: CENP-A phospho Ser 16. Lane 4: CENP-A phospho Ser 18.)
WB (Western Blot) (CENP-A phospho Ser18 antibody (pAb) tested by Western blot. Top: Recombinant CENP-A (20 ng) was probed with CENP-A phospho Ser18 antibody (1:100 dilution) (A) or with anti-centromere antibody (ACA) (B). CENP-A phospho Ser18 antibody does not detect recombinant CENP-A. Bottom: HeLa nuclear extract (20 ug) was probed with CENP-A phospho Ser18 antibody (1:250 dilution). Lane 1: CENP-A phospho-Ser18 antibody. Lane 2: anti-centromere antibody (ACA).)
IF (Immunofluorescence) (CENP-A phospho Ser18 antibody (pAb) tested by immunofluorescence. Detection of CENP-A phospho Ser18 by immunofluorescence. HeLa cells were stained with CENP-A phospho Ser18 antibody at a 1:100 dilution. Green: CENP-A phospho Ser18 antibody (pAb) Blue: DAPI)
ICC (Immunocytochemistry) (1. Coat coverslips with 1 % gelatin-coating solution for 2 hours at room temperature (RT): rinse with distilled water, and let to dry overnight. Before plating the cells, wash the coated coverslips briefly with PBS.2. Fix the cells with 4% paraformaldehyde solution (in PBS, pH 7.2), for 15 min at RT.3. Wash 2 x 3 min with PBS.4. Permeabilize the cells with 0.1% Triton X-100 solution (in PBS. pH 7.2) for 5 min on ice.5. Wash 2 x 3 min with PBS.6. Incubate the cells in blocking buffer (0.3M glycine in PBS, 2% BSA) for 30 min at RT.7. Incubate the cells with primary antibody: anti-phospho Erk 1,2 clonal antibody at the dilution of 1:100 - 1 :400 in antibody dilution buffer (PBS, 1 % BSA) for 1 hour at RT in humid chamber.8. Wash 2 x 3 min with PBS.9. Apply the secondary antibody (in this case, the goat anti-rabbit IgG-FITC from Jackson Immunoresearch, cat. # 111-095-003, was used at 1 :300 in antibody dilution buffer, and cells were incubated for 1 hour at RT in dark).10. Wash 3 x 3 min with PBS.11. Rinse once with distilled water.12. Mount the slide for observation, with a drop of anti-fade mounting medium.)
WB (Western Blot) (Western Immunoblottlng solutions:Wash buffer: 1x Tris Buffered Saline (TBS): 0.1% Triton X-100Blocking buffer: 1xTBS: 0.1% Triton X-100: 5% BSA (used with the primary antibody))
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (Anti-Phospho-KDR/FLK1-Y996 Pab is used in Western blot to detect Phospho-KDR/FLK1-Y996 in HMVEC cell line lysate.Endothelial cells were stimulated with 50ug/ml VEGF for 5min; 20ug lysate from HMVEC was loaded onto an 8% gel; for Western blot, membranes were incubated O/N with Phospho-KDR/FLK1-Y996 Antibody (AAA283770)diluted to 1:500 in 1% Milk/TBST.Data and Protocol kindly provided by Dr. Weis from Cheresh Lab, UCSD.)
DB (Dot Blot) (Dot blot analysis of Phospho-IKKB-S672 Antibody Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
IHC (Immunohistochemistry) (Formalin-fixed and paraffin-embedded human canccer tissue reacted with the primary antbody, which was peroxidase-conjugated to the secondary antibody, which followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemisty; clinical relevance has not been evaluated. BC= Breast Carcinoma; HC= Hepatocarcinoma.)
DB (Dot Blot) (Dot blot analysis of Phospho-Cdk7-T170 Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
WB (Western Blot) (Western blot analysis of extracts from Hela and MCF-7 cells, untreated or lamda phosphatase-treated, using Phospho-CDK7(please inquire) Antibody (upper) or Beta-actin (lower).)
WB (Western Blot) (Western blot analysis of lysates from NIH/3T3 cell line, untreated or treated with ? phosphatase, using 459667101(Cat. #AAA283874)(upper) or Tubulin (lower).)
WB (Western Blot) (The CDK7-T170 Pab is used in Western blot to detect CDK7-T170 in Ramos tissue lysate.)
WB (Western Blot) (Western blot analysis of Phospho-RAF1-pS338 Antibody in human TPA activated Hela cell line lysates. Phospho-RAF1 (arrow) was detected using the purified PAb. (0: without TPA; 1: 60ug/ml TPA, 15min; 2: 60ug/ml TPA, 30min; 3: 60ug/ml TPA, 45min; 4: 125ug/ml TPA, 15min; 5: 125ug/ml TPA, 30min; 6: 125ug/ml TPA, 45min; 7: 250ug/ml TPA, 15min; 8: 250ug/ml TPA, 30min; 9: 250ug/ml, 45min))
DB (Dot Blot) (Dot blot analysis of anti-RAF1-pS338 Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
DB (Dot Blot) (Dot blot analysis of Phospho-ERBB2-Y1139 Antibody Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
WB (Western Blot) (Western blot analysis of extracts from A431 cells,untreated or treated with EGF,100ng/ml, using phospho-ERBB2-Y1139(left) or ERBB2 antibody(right))
DB (Dot Blot) (Dot blot analysis of anti-Phospho-GFAP-S8 Antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
DB (Dot Blot) (Dot blot analysis of Phospho-ERBB2-S1107 Antibody Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
WB (Western Blot) (Western blot analysis of extracts from A431 cells, untreated or treated with EGF, using phospho-ERBB2-S1107 (left) or ErBB2 antibody(right).)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (Western blot analysis of anti-Phospho-STAT1 Pab in mouse brain tissue lysate (35ug/lane). Phospho-STAT1(arrow) was detected using the purified Pab.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using SRF (Phospho-Ser77) antibody. The picture on the right is treated with the synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from Jurkat cells, treated with PMA (125ng/ml, 30mins), using SRF (Phospho-Ser77) antibody. The lane on the right is treated with the synthesized peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed MCF cells using Estrogen Receptor-a(Phospho-Ser167) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Estrogen Receptor-a(Phospho-Ser167) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from MCF7 cells using Estrogen Receptor-a(Phospho-Ser167) Antibody(Lane 2) and the same antibody preincubated with blocking peptide(Lane1).)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from 293 cells, treated with calf intestinal phosphatase (CIP), using Keratin 8 (Phospho-Ser74) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using Keratin 8(Phospho-Ser74) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from HepG2 cells untreated or treated with EGF using Keratin 8(Phospho-Ser74) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from 3T3 cells, treated with serum or calf intestinal phosphatase (CIP), using MARCKS (phospho-Ser170) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using MARCKS(Phospho-Ser170) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from MCF cells untreated or treated with EGF using MARCKS(phospho-Ser170) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using Cyclin B1(phospho-Ser147) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Cyclin B1(Phospho-Ser147) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from MDA cells untreated or treated with Anisomycin using Cyclin B1(phospho-Ser147) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from Hela cells, treated with calf intestinal phosphatase (CIP), using HSP90B (Phospho-Ser254) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from Hela cells untreated(lane 1) or treated with hot shock(lane 2) using HSP90B(Phospho-Ser254) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Pricing
What Are Phospho Antibodies?
Protein phosphorylation is a process where a phosphate group is added to certain amino acid residues of a protein – usually serine (S), threonine (T), or tyrosine (Y) - by enzymes called kinases. This process is integral in controlling cellular signaling, cellular growth, and other biological functions.
Our catalog includes a wide range of phospho-specific antibodies that can accurately detect this important marker. They perform strongly in widely-used laboratory applications such as Western blot, flow cytometry, immunohistochemistry, and immunofluorescence microscopy. We value your trust in us and are committed to providing top-quality products and services. All of our antibodies are guaranteed to work for the applications and species indicated on our website & associated product pages.
What Are The Key Applications of Phospho Antibodies?
1. Western Blotting
One of the first steps a researcher can take in utilizing these phospho-specific antibodies, is to check if the antibody works using a technique referred to as “Western blot”. For those unfamiliar, Western Blot aids in showing whether the protein that the antibody recognizes is appearing at the correct/expected size. These phospho-specific antibodies should also be able to detect changes in the target protein’s phosphorylation (on/off state) when cells are stimulated in certain ways.
2. Staining of Fixed Cells (Immunocytochemistry)
Another routine use of these phospho-specific antibodies, is to test if the antibody is able to demonstrate similar performance when used on fixed cells (intact cells that have been preserved) as it did in the Western blot tests. It is an important aspect in many cases to confirm that the antibody works in actual intact cell samples. Ideally, the method used for cellular fixation should be the same as what is used in pathology labs (like using 10% formalin). To check if the antibody works well in tissue sections (FFPE), researchers will often test it on fixed cells that are processed similar to tissue samples.
3. Specificity Tests Using Peptides
In order to make sure that the antibody is only binding to the right target:
Laboratory technicians will mix the antibody with phospho-peptides (short segments of the protein containing the phosphate group modification).
If the antibody signal disappears, it is confirmation that it is binding to the correct phosphorylated location.
A more robust test is to use both the phosphorylated and non-phosphorylated (dephosphorylated) versions of the protein. The antibody should react only with the phosphorylated one.
Another method sometimes utilized is to treat the sample with an enzyme, such as alkaline phosphatase, that specifically removes phosphate groups. If the antibody signal disappears after this, it also confirms specificity.
4. Genetic Confirmation
As a final step, scientists can genetically manipulate the nucleotide sequence and alter the target protein by removing the exact site where phosphorylation happens. If the antibody no longer appears to detect the modified protein, it is strong evidence supporting the antibody being specific for that phosphorylated site.
Why Buy Phospho Antibodies Through Us?
The production laboratory adheres to strict and consistent protocols prior to releasing any of these phospho-specific antibodies:
Standard methods and proper controls in all tests to ensure high quality.
These antibodies are tested and validated in different cell types and species.
High quality control criterion to ensure each batch is consistent, so you will obtain reliable results every time.
FAQ
1. What Are Phospho-Specific Antibodies?
Phospho-specific antibodies are made to detect proteins only when they have a phosphate group linked to a specific amino acid residue. This empowers scientists understand if a protein is "turned on" or active, based on its phosphorylation state.
2. How to Detect Phosphorylated Proteins in a Western Blot?
To find out if a protein is phosphorylated using Western blot:
Use a phospho-specific antibody that binds only to the phosphorylated form of the protein.
You can also use a “regular” antibody for the same amino acid sequence of the protein that the phospho-specific antibody is binding to (but in this case, this antibody will not bind if there is a phosphate group present) in order to compare how much of it is phosphorylated versus how much is non-phosphorylated (or “total” protein, if the “normal” antibody’s epitopes are non-phospho-site-specific).
3. How to Choose the Best Antibody?
Here are some simple tips to help you pick the right antibody:
Know your target
Match your sample characteristics
Confirm the intended use is appropriate
Check “host” and “type”
Check the “quality” of the presented data/images
Appraise whether the available validation meets your needs
Submit a Question
Please complete the form below and a representative will contact you as soon as possible.
Request more Information
Please complete the form below and a representative will contact you as soon as possible.
Request a Manual
Please complete the form below and a representative will contact you as soon as possible.
Request a Quote
Please complete the form below and a representative will contact you as soon as possible.